ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
6.40
+0.28 (4.58%)
At close: Aug 29, 2025, 4:00 PM
6.28
-0.12 (-1.88%)
After-hours: Aug 29, 2025, 4:53 PM EDT
ImmuCell Revenue
ImmuCell had revenue of $6.44M in the quarter ending June 30, 2025, with 17.76% growth. This brings the company's revenue in the last twelve months to $28.27M, up 21.75% year-over-year. In the year 2024, ImmuCell had annual revenue of $26.49M with 51.64% growth.
Revenue (ttm)
$28.27M
Revenue Growth
+21.75%
P/S Ratio
1.99
Revenue / Employee
$376,997
Employees
75
Market Cap
57.89M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.49M | 9.02M | 51.64% |
Dec 31, 2023 | 17.47M | -1.10M | -5.90% |
Dec 31, 2022 | 18.57M | -675.01K | -3.51% |
Dec 31, 2021 | 19.24M | 3.90M | 25.43% |
Dec 31, 2020 | 15.34M | 1.62M | 11.80% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ICCC News
- 16 days ago - ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025 - GlobeNewsWire
- 19 days ago - ImmuCell Announces Bank Debt Refinancing - GlobeNewsWire
- 24 days ago - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025 - GlobeNewsWire
- 7 weeks ago - ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025 - GlobeNewsWire
- 2 months ago - ImmuCell Embarks on CEO Succession Planning Process - GlobeNewsWire
- 3 months ago - ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders - GlobeNewsWire
- 3 months ago - ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript - Seeking Alpha